Dr Stephen Hiscox
Prosiectau fel Prif Ymchwiliwr
- Combined use of AZD0530 and fulvestrant in breast cancer (01.04.2009 - 31.03.2010)
- Exploration of CD44 as a mediator of a drug resistant phenotype in breast cancer (01.10.2011 - 30.09.2014)
- Exploring the impact of anti-oestrogen resistance on the ability of breast cancer cells to modulate bone cell function (01.10.2013 - 30.09.2016)
- FAK as a novel therapeutic target in endocrine-resistant and endocrine-sensitive breast cancer (01.10.2011 - 30.09.2014)
- The therapeutic potential of focal adhesion kinase in endocrine-responsive/resistant breast cancer and the HER2+breast cancer subtype (01.11.2010 - 31.07.2012)
Prosiectau fel Cyd-Ymchwiliwr
- Inducing tyrosine kinase receptor degradation as a novel therapeutic strategy in breast cancer (01.10.2010 - 31.12.2014)
- Vacation studentship (27.06.2011 - 26.08.2011)